TABLE H-1 WOMEN'S HEALTH STUDIES WITH MULTI-INSTITUTE FUNDING

Study Title

Contributing Institutes

Estimate of Costs by Institute ($)

Period of Study

Number of Subjects

Women's Health Trial: Feasibility Study in Minority Populations

NCI

NHLBI

NIDR

12,300,000

1,106,000

300,000

13,706,000

2 years

2,250

WHT Feasibility Study in Minority Populations: Salivary Study

NIDR (same as above)

300,000 (part of above)

2 years (same as above period)

200 (part of above sample)

Postmenopausal Estrogen/Progestin Interventions (PEPI)

NHLBI

NICHD

NIAMS

NIA

NIDDK

15,187,000

3,535,355

2,025,000

578,000

535,000

21,860,355

10 years

875

Breast Cancer Prevention Trial - Tamoxifen

NCI

NHLBI

NIAMS

65,820,000

7,931,000

2,136,000

75,887,000

7 years

16,000

Study of Osteoporotic Fractures

NIAMS

NIA

32,489,000

14,615,191

47,104,191

11 years

9,700

Efficacy of Estrogen in Hyperprolactinemic Amenorrhea

NIDDK

ORWH

1,043,032

NA

1,043,032

5 years

100

Membrous Lupus Nephropathy

NIDDK

NCI

1,257,000

NA

1,257,000

9 years

16 to date (75% female)

Combination Radioiodine and Adriamycin for Follicular Thyroid Carcinoma

NIDDK

NCI

1,499,000

NA

1,499,000

6 years

22 to date (75% female)

Vitamin E, Betacarotene and Aspirin in Women

NCI

NHLBI

8,474,728

8,348,000

16,822,728

5 years

40,000

Long-Term Outcome of Obesity Treatment in Minority Women

NIDDK

ORMH

3,534,011

6 years

600



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement